Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue (2016 - 2024)

Seres Therapeutics (MCRB) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $95.4 million as the latest value for Q2 2024.

  • Quarterly Non-Current Deffered Revenue changed 0.46% to $95.4 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $95.4 million through Jun 2024, changed 0.46% year-over-year, with the annual reading at $95.4 million for FY2023, 3.17% up from the prior year.
  • Non-Current Deffered Revenue hit $95.4 million in Q2 2024 for Seres Therapeutics, roughly flat from $95.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $95.4 million in Q4 2023 to a low of $78.4 million in Q2 2021.
  • Historically, Non-Current Deffered Revenue has averaged $88.8 million across 5 years, with a median of $89.7 million in 2021.
  • Biggest YoY gain for Non-Current Deffered Revenue was 2820.89% in 2020; the steepest drop was 12.09% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $85.6 million in 2020, then rose by 1.67% to $87.0 million in 2021, then rose by 6.24% to $92.4 million in 2022, then rose by 3.17% to $95.4 million in 2023, then changed by 0.0% to $95.4 million in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for MCRB at $95.4 million in Q2 2024, $95.4 million in Q1 2024, and $95.4 million in Q4 2023.